MXPA03005099A - Oral extended release formulation of gepirone. - Google Patents

Oral extended release formulation of gepirone.

Info

Publication number: MXPA03005099A
Authority: MX; Mexico
Prior art keywords: gepirone; release formulation; extended release; oral extended; oral
Prior art date: 2000-12-08

Application number

MXPA03005099A

Other languages

Spanish (es)

Inventor

John Francis Engelhart

Original Assignee

Akzo Nobel Nv

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2000-12-08

Filing date

2001-11-30

Publication date

2004-02-12

2001-11-30 Application filed by Akzo Nobel Nv filed Critical Akzo Nobel Nv

2004-02-12 Publication of MXPA03005099A publication Critical patent/MXPA03005099A/en

Links

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
- A61K47/38—Cellulose; Derivatives thereof
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
- A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Pharmacology & Pharmacy (AREA)
Animal Behavior & Ethology (AREA)
Life Sciences & Earth Sciences (AREA)
Veterinary Medicine (AREA)
Public Health (AREA)
General Health & Medical Sciences (AREA)
Medicinal Chemistry (AREA)
Epidemiology (AREA)
General Chemical & Material Sciences (AREA)
Bioinformatics & Cheminformatics (AREA)
Engineering & Computer Science (AREA)
Neurology (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Biomedical Technology (AREA)
Chemical Kinetics & Catalysis (AREA)
Organic Chemistry (AREA)
Neurosurgery (AREA)
Pain & Pain Management (AREA)
Psychiatry (AREA)
Inorganic Chemistry (AREA)
Medicinal Preparation (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

MXPA03005099A 2000-12-08 2001-11-30 Oral extended release formulation of gepirone. MXPA03005099A (en)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
EP00204388		2000-12-08
PCT/EP2001/014189 WO2002045753A2 (en)	2000-12-08	2001-11-30	Oral extended release formulation of gepirone

Publications (1)

Publication Number	Publication Date
MXPA03005099A true MXPA03005099A (en)	2004-02-12

Family

ID=8172397

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
MXPA03005099A MXPA03005099A (en)	2000-12-08	2001-11-30	Oral extended release formulation of gepirone.

Country Status (19)

Country	Link
EP (1)	EP1343504A2 (en)
JP (1)	JP2004517083A (en)
KR (1)	KR20040018314A (en)
CN (1)	CN1479620A (en)
AR (1)	AR031461A1 (en)
AU (1)	AU2002226371A1 (en)
BR (1)	BR0115976A (en)
CA (1)	CA2436692A1 (en)
CZ (1)	CZ20031589A3 (en)
EC (1)	ECSP034627A (en)
HU (1)	HUP0401021A2 (en)
IL (1)	IL155855A0 (en)
MX (1)	MXPA03005099A (en)
NO (1)	NO20032581D0 (en)
PL (1)	PL362445A1 (en)
RU (1)	RU2003120446A (en)
SK (1)	SK6942003A3 (en)
WO (1)	WO2002045753A2 (en)
ZA (1)	ZA200303915B (en)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
EP1545469A1 (en) *	2002-09-24	2005-06-29	Akzo Nobel N.V.	Method to improve pharmaceutical tablets having a matrix of cellulose ether
CN101076320A (en) *	2004-11-05	2007-11-21	法布雷－克雷默控股公司	High-dosage extended-release formulation of gepirone
EP3657966A1 (en) *	2017-07-26	2020-06-03	Abbott Laboratories	Nutritional tablets and methods of making the same
CN109745323A (en) *	2017-11-01	2019-05-14	四川科瑞德制药股份有限公司	Azapirone compound improves the active purposes of parasympathetic nerve

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US5478572A (en) *	1994-09-06	1995-12-26	Bristol-Myers Squibb Co.	Gepirone dosage form

2001
- 2001-11-30 MX MXPA03005099A patent/MXPA03005099A/en unknown
- 2001-11-30 IL IL15585501A patent/IL155855A0/en unknown
- 2001-11-30 AU AU2002226371A patent/AU2002226371A1/en not_active Abandoned
- 2001-11-30 CZ CZ20031589A patent/CZ20031589A3/en unknown
- 2001-11-30 WO PCT/EP2001/014189 patent/WO2002045753A2/en not_active Application Discontinuation
- 2001-11-30 HU HU0401021A patent/HUP0401021A2/en unknown
- 2001-11-30 KR KR10-2003-7007555A patent/KR20040018314A/en not_active Application Discontinuation
- 2001-11-30 BR BR0115976-3A patent/BR0115976A/en not_active Application Discontinuation
- 2001-11-30 JP JP2002547535A patent/JP2004517083A/en not_active Withdrawn
- 2001-11-30 RU RU2003120446/15A patent/RU2003120446A/en not_active Application Discontinuation
- 2001-11-30 SK SK694-2003A patent/SK6942003A3/en unknown
- 2001-11-30 CA CA002436692A patent/CA2436692A1/en not_active Abandoned
- 2001-11-30 EP EP01995688A patent/EP1343504A2/en not_active Withdrawn
- 2001-11-30 PL PL01362445A patent/PL362445A1/en not_active Application Discontinuation
- 2001-11-30 CN CNA018201792A patent/CN1479620A/en active Pending
- 2001-12-07 AR ARP010105683A patent/AR031461A1/en not_active Application Discontinuation
2003
- 2003-05-20 ZA ZA200303915A patent/ZA200303915B/en unknown
- 2003-05-28 EC EC2003004627A patent/ECSP034627A/en unknown
- 2003-06-06 NO NO20032581A patent/NO20032581D0/en not_active Application Discontinuation

Also Published As

Publication number	Publication date
AU2002226371A1 (en)	2002-06-18
CN1479620A (en)	2004-03-03
EP1343504A2 (en)	2003-09-17
ZA200303915B (en)	2004-08-20
ECSP034627A (en)	2004-09-28
WO2002045753A3 (en)	2002-08-29
SK6942003A3 (en)	2003-10-07
JP2004517083A (en)	2004-06-10
WO2002045753A2 (en)	2002-06-13
KR20040018314A (en)	2004-03-03
RU2003120446A (en)	2005-02-20
AR031461A1 (en)	2003-09-24
IL155855A0 (en)	2003-12-23
BR0115976A (en)	2003-12-30
CZ20031589A3 (en)	2003-11-12
HUP0401021A2 (en)	2004-09-28
NO20032581L (en)	2003-06-06
PL362445A1 (en)	2004-11-02
CA2436692A1 (en)	2002-06-13
NO20032581D0 (en)	2003-06-06

Publication	Publication Date	Title
EG23943A (en)	2008-01-22	Flash-melt oral dosage formulation
AU9208601A (en)	2002-04-22	Delayed release pharmaceutical formulations
ZA200007715B (en)	2001-06-20	Stable extended release oral dosage composition.
ZA200007714B (en)	2001-08-16	Extended release oral dosage composition.
AU6089200A (en)	2001-02-05	Rapid immediate release oral dosage form
HK1058003A1 (en)	2004-04-30	Sustained release ranolazine formulations
MXPA03002569A (en)	2003-10-14	Controlled release formulations for oral administration.
HUP0301177A3 (en)	2006-07-28	Ion-strength independent sustained release pharmaceutical formulation
EP1297828A4 (en)	2007-05-02	Oral formulations for localized colonic release and the method of preparation thereof
AU2001248336A1 (en)	2001-09-17	Controlled release oral solid forms containing mesalazine as active agent
HK1060365A1 (en)	2004-08-06	Water-soluble blocking wax formulation
HUP0204417A3 (en)	2005-03-29	Oral ciprofloxacin-composition of controlled release
IL148908A0 (en)	2002-09-12	Oral controlled release formulations
HUP0401599A3 (en)	2007-03-28	Extended release oral dosage form
MXPA03005099A (en)	2004-02-12	Oral extended release formulation of gepirone.
AU2001241187A1 (en)	2001-10-03	Sustained release oral preparations
EP1357898A4 (en)	2005-07-13	Improved controlled release oral dosage form
GB2363073B (en)	2004-10-20	Oral rehydration formulation
AU8254101A (en)	2002-03-22	Medicinal compositions
AU2001293278A1 (en)	2003-04-01	Tableted oral extended release dosage form
ZA200105511B (en)	2002-06-26	Oral solid pharmaceutical formulations with ph dependent multiphasic release
HU0900677D0 (en)	2010-05-28	Extended release oral dosage composition
AUPQ780600A0 (en)	2000-06-22	Modified release formulation
SI1216032T1 (en)	2008-06-30	Oral controlled release formulations
GB0008029D0 (en)	2000-05-24	New vaccine formulations